Open Access

Sarcopenia does not predict outcome in patients with CNS lymphoma undergoing systemic therapy

  • Authors:
    • Vincenzo Ferraro
    • Maximilian Thormann
    • Mattes Hinnerichs
    • Maciej Pech
    • Denise Wolleschak
    • Dimitrios Mougiakakos
    • Andreas Wienke
    • Alexandra Strobel
    • Vanja Zeremski
    • Alexey Surov
    • Jazan Omari
  • View Affiliations

  • Published online on: August 22, 2022     https://doi.org/10.3892/ol.2022.13475
  • Article Number: 355
  • Copyright: © Ferraro et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Low skeletal muscle mass as a proxy parameter for sarcopenia acts as a non‑invasive imaging marker that is associated with poor prognosis in numerous types of cancer. The present study aimed to assess the influence of body composition parameters on overall survival (OS) and progression free survival (PFS) in patients diagnosed with primary central nervous system lymphoma (PCNSL). A total of 98 patients with PCNSL treated at University Hospital Magdeburg (Magdeburg, Germany) from 2013‑2019 were retrospectively studied. Patients with a pre‑treatment staging computed tomography (CT) scan that included the third lumbar vertebra were reviewed for analysis. Skeletal muscle area (SMA), skeletal muscle index (SMI), mean muscle density and skeletal muscle gauge (SMG) were measured on the CT scan prior to treatment. Parameters were associated with OS and PFS. Overall, 72 patients were included in the present study. Results of the present study demonstrated that the median OS was 10 months (range, 1‑181 months), and 37 patients (51.4%) presented with sarcopenia. Moreover, the median OS was 7 months in the sarcopenic group and 32 months in the non‑sarcopenic group. Results of the present study further illustrated that SMI, SMA, density and SMG did not exert a significant effect on OS. Notably, the median PFS was 2.5 months in the low SMI group and 10 months in the normal SMI group. Body composition parameters did not exert a significant effect on PFS. Overall, the results of the present study demonstrated that sarcopenia was not a risk factor for decreased OS or PFS in patients with PCNSL undergoing systemic treatment.
View Figures
View References

Related Articles

Journal Cover

October-2022
Volume 24 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ferraro V, Thormann M, Hinnerichs M, Pech M, Wolleschak D, Mougiakakos D, Wienke A, Strobel A, Zeremski V, Surov A, Surov A, et al: Sarcopenia does not predict outcome in patients with CNS lymphoma undergoing systemic therapy. Oncol Lett 24: 355, 2022
APA
Ferraro, V., Thormann, M., Hinnerichs, M., Pech, M., Wolleschak, D., Mougiakakos, D. ... Omari, J. (2022). Sarcopenia does not predict outcome in patients with CNS lymphoma undergoing systemic therapy. Oncology Letters, 24, 355. https://doi.org/10.3892/ol.2022.13475
MLA
Ferraro, V., Thormann, M., Hinnerichs, M., Pech, M., Wolleschak, D., Mougiakakos, D., Wienke, A., Strobel, A., Zeremski, V., Surov, A., Omari, J."Sarcopenia does not predict outcome in patients with CNS lymphoma undergoing systemic therapy". Oncology Letters 24.4 (2022): 355.
Chicago
Ferraro, V., Thormann, M., Hinnerichs, M., Pech, M., Wolleschak, D., Mougiakakos, D., Wienke, A., Strobel, A., Zeremski, V., Surov, A., Omari, J."Sarcopenia does not predict outcome in patients with CNS lymphoma undergoing systemic therapy". Oncology Letters 24, no. 4 (2022): 355. https://doi.org/10.3892/ol.2022.13475